Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Capecitabine + Oxaliplatin + Toripalimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Capecitabine||Xeloda||R340||Chemotherapy - Antimetabolite 11||Xeloda (capecitabine) is an antimetabolite that when activated to 5-FU ultimately inhibits DNA synthesis and cell division (NCI Drug Dictionary).|
|Oxaliplatin||Eloxatin||Diaminocyclohexane Oxalatoplatinum||Chemotherapy - Platinum 6||Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity, and is FDA approved for colorectal cancer (FDA.gov).|
|Toripalimab||JS001|JS-001|TAB001||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 65||Toripalimab (JS001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response and decreased tumor growth (PMID: 28317872; PMID: 32277740, PMID: 32406293, PMID: 32321714).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||stomach cancer||not applicable||Capecitabine + Oxaliplatin + Toripalimab||Phase Ib/II||Actionable||In a Phase I/II trial, Toripalimab (JS001) in combination with Eloxatin (oxaliplatin) and Xeloda (capecitabine) resulted in an objective response rate (ORR) of 66.7% (12/18, 1 complete response, 11 partial responses) and a disease control rate of 88.9% (16/18) in patients with chemotherapy-naive advanced gastric cancer, with a progression-free survival of 5.8 months and overall survival not reached, same ORRs (66.7%) were observed in CD274 (PD-L1)-positive and -negative groups (PMID: 31236579; NCT02915432).||31236579|
|Unknown unknown||gastric adenocarcinoma||not applicable||Capecitabine + Oxaliplatin + Toripalimab||Phase II||Actionable||In a Phase II trial, Toripalimab (JS001) in combination with Xeloda (capecitabine) and Eloxatin (oxaliplatin) resulted in an objective response rate of 54.5% (18/33) and a disease control rate of 84.8% (28/33) in patients with metastatic gastric adenocarcinoma, with a median duration of response of 8.3 months (J Clin Oncol 38: 2020 (suppl; abstr e15083); NCT02915432).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|